A phase I, open label, single center, dose escalation study to assess the pharmacokinetics, safety and tolerability of a single dose of a new extended long-acting formulation of octreotide [octreotide pamoate] administered i.m. [intramuscular] in healthy cholecystectomized volunteers

Trial Profile

A phase I, open label, single center, dose escalation study to assess the pharmacokinetics, safety and tolerability of a single dose of a new extended long-acting formulation of octreotide [octreotide pamoate] administered i.m. [intramuscular] in healthy cholecystectomized volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Octreotide (Primary)
  • Indications Malignant carcinoid syndrome; Malignant thymoma; Neuroendocrine tumours; Prostate cancer
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 16 Feb 2011 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 26 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top